The State Street SPDR S&P Biotech ETF (XBI) was launched on January 31, 2006, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Biotech segment of ...

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, ...

Raise large amounts of capital with an initial public offering, burn cash while navigating clinical trials, then submit a new ...

Amid the trying circumstances in the market right now, investors may be well served to target the best biotech ETFs to buy. Fundamentally, these exchange-traded funds benefit from permanent relevance.

This was a new position; the IBB stake now accounts for 8.7% of Florin Court Capital LLP’s 13F AUM Top five holdings after the filing: ICLN: $16.6 million (13.0% of AUM) IBB: $11.1 million (8.7% of ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

This rally in Illumina proved a shot in the arm for one of the most Illumina-sensitive funds, the ARK Genomic Revolution ETF (BATS:ARKG). It surged about 4% this week to outperform broader biotech ...

There is no denying that the pandemic has opened up investment opportunities in the biotech sector by triggering a race to introduce vaccines and treatment options. Moreover, increasing mergers and ...

Direxion Biotech Bull 3X (LABU) doubled over the past year by delivering three times the daily biotech index return. FDA drug approvals often trigger 20% to 50% single-day stock jumps that LABU’s ...

Investors and vaccine makers like Moderna MRNA and Johnson & Johnson JNJ have reasons to cheer the latest update concerning the application of COVID-19 booster shots. In an effort to combat the ...